Fluorine-18-DCFPyL

Unassigned

New Medicines

Prostate cancer - imaging

Information

Radiopharmaceutical
Curium
Progenics Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission tomography (PET) enhancer
The age-standardised incidence of prostate cancer in England in 2016 was 173.7 per 100,000 in 2016 [1].
Prostate cancer - imaging
Intravenous